BioCity Biopharma
China - Wuxi
PharmaceuticalFocus: Small Molecules, Antibodies
BioCity Biopharma is a life sciences company focused on Small Molecules, Antibodies.
OncologyNephrologyMetabolic DiseasesNeurology
Open Jobs
1
Pipeline & Clinical Trials
BC3402 Injection
Hematologic MalignancyClinical Trials (1)
NCT05690425A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML
Phase 1BC2027 for Injection
Advanced Solid MalignanciesClinical Trials (1)
NCT07368478A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies
Phase 1BC3195
Advanced CancerClinical Trials (1)
NCT06548672A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer
Phase 1Phase 1
Clinical Trials (1)
NCT05970822Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML
Phase 1Drug: BC3195 for Injection
Locally Advanced or Metastatic Solid TumorsClinical Trials (1)
NCT05957471Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors
Phase 1SC0245
Small Cell Lung CancerClinical Trials (1)
NCT05731518SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Phase 1/2BC3402 injection
Hepatocellular CarcinomaClinical Trials (1)
NCT06111326BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma
Phase 1/2SC0191
Serous Ovarian CancerClinical Trials (1)
NCT06055348SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer
Phase 1/2Dapagliflozin
Type 1 Diabetes Mellitus With Diabetic NephropathyClinical Trials (1)
NCT06072326dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation
Phase 2Placebo of SC0062
Diabetic Kidney DiseaseClinical Trials (1)
NCT05687890A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
Phase 2SC0062 strength 10mg
IgA Nephropathy (IgAN)Clinical Trials (1)
NCT06819826A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
Phase 3Open Jobs (1)
Interview Prep Quick Facts
Founded: 2022
Portfolio: 11 clinical trials
Open Roles: 1 active job